Home >> Research Area >>Neuroscience>>COX>> Meclofenamate Sodium

Meclofenamate Sodium

CAS# 6385-02-0

Meclofenamate Sodium

Catalog No. BCC5490----Order now to get a substantial discount!

Product Name & Size Price Stock
Meclofenamate Sodium: 5mg $12 In Stock
Meclofenamate Sodium: 10mg Please Inquire In Stock
Meclofenamate Sodium: 20mg Please Inquire Please Inquire
Meclofenamate Sodium: 50mg Please Inquire Please Inquire
Meclofenamate Sodium: 100mg Please Inquire Please Inquire
Meclofenamate Sodium: 200mg Please Inquire Please Inquire
Meclofenamate Sodium: 500mg Please Inquire Please Inquire
Meclofenamate Sodium: 1000mg Please Inquire Please Inquire
Related Products
  • Licofelone

    Catalog No.:BCC4432
    CAS No.:156897-06-2
  • Lumiracoxib

    Catalog No.:BCC4440
    CAS No.:220991-20-8
  • Bufexamac

    Catalog No.:BCC4427
    CAS No.:2438-72-4
  • Triflusal

    Catalog No.:BCC4443
    CAS No.:322-79-2
  • Nabumetone

    Catalog No.:BCC4434
    CAS No.:42924-53-8

Quality Control of Meclofenamate Sodium

Number of papers citing our products

Chemical structure

Meclofenamate Sodium

3D structure

Chemical Properties of Meclofenamate Sodium

Cas No. 6385-02-0 SDF Download SDF
PubChem ID 4038 Appearance Powder
Formula C14H10Cl2NNaO2 M.Wt 318.13
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 250 mg/mL (785.84 mM; Need ultrasonic)
Chemical Name sodium;2-(2,6-dichloro-3-methylanilino)benzoate
SMILES CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)[O-])Cl.[Na+]
Standard InChIKey OGPIIGMUPMPMNT-UHFFFAOYSA-M
Standard InChI InChI=1S/C14H11Cl2NO2.Na/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;/h2-7,17H,1H3,(H,18,19);/q;+1/p-1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Meclofenamate Sodium Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Meclofenamate Sodium Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Meclofenamate Sodium

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.1434 mL 15.7168 mL 31.4337 mL 62.8674 mL 78.5842 mL
5 mM 0.6287 mL 3.1434 mL 6.2867 mL 12.5735 mL 15.7168 mL
10 mM 0.3143 mL 1.5717 mL 3.1434 mL 6.2867 mL 7.8584 mL
50 mM 0.0629 mL 0.3143 mL 0.6287 mL 1.2573 mL 1.5717 mL
100 mM 0.0314 mL 0.1572 mL 0.3143 mL 0.6287 mL 0.7858 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Meclofenamate Sodium

Comparison of the kinetics of sodium meclofenamate versus meclofenamic acid after oral administration to sheep.[Pubmed:8578896]

Zentralbl Veterinarmed A. 1995 May;42(3):177-83.

Meclofenamates are non-steroidal anti-inflammatory agents used in ruminants for the prevention and the treatment of anaphylactic processes. The objective of the present work was to study possible kinetic variations due to the chemical form of meclofenamates administered by the oral route to adult sheep. Six Rubia del Molar female sheep (2-3 years old, 47-57 kg) were used. Initially, an intravenous administration of sodium meclofenamate (2.2 mg/kg bwt) was given; the obtained kinetic results were in agreement with data from other authors. Oral administrations (20 mg/kg bwt) of sodium meclofenamate and meclofenamic acid were then given. When the reticular groove was opened, both drug forms showed a single meclofenamate plasma peak; t2max were 60.0 +/- 10.61 min and 127.50 +/- 22.5 min for the sodium and acid form, respectively. The elimination rate constants (beta) were not significantly different, but the absorption half-lives were (14.69 +/- 3.21 min for the sodium form and 61.07 +/- 21.7 min for the acid form). The bioavailability was 48.6 +/- 4.3% for sodium meclofenamate and 65.1 +/- 2.8% for meclofenamic acid. Thus, the chemical form (sodium versus acid) alters the oral bioavailability and tmax of meclofenamates in adult sheep. These findings agree with the behaviour of meclofenamates in man.

Efficacy of meclofenamate sodium (Meclomen) in the treatment of rapidly progressive periodontitis.[Pubmed:8227450]

J Clin Periodontol. 1993 Oct;20(9):635-40.

This 6-month, double-blind, controlled clinical trial determined the efficacy of the non-steroidal anti-inflammatory drug, Meclofenamate Sodium (Meclomen), as an adjunct to scaling and root planing in the treatment of rapidly progressive periodontitis (RPP). 22 subjects (7 male, 15 female) aged 36.5 +/- 7.88 years with RPP and disease-active sites as determined by pretreatment bone scan had standardized radiographs at baseline and 6 months, and clinical measurements at baseline, 3 and 6 months. Following full-mouth scaling and root planing, subjects were randomly assigned to either a placebo, 50 or 100 mg Meclofenamate Sodium bid group. Bone change over the 6-month period as assessed by subtraction radiography was the primary efficacy determinant. Specialized software was used to isolate the lesion from the subtraction image and to measure bone change along the root surface. ANOVA using the subject as the unit of analysis revealed a significant dose response (p < 0.001) with the placebo group having a mean bone loss of 0.42 +/- 0.06 mm and the low and high dose groups having mean bone gains of 0.07 +/- 0.05 and 0.20 +/- 0.07 mm, respectively. These findings indicate that Meclofenamate Sodium may be a useful adjunct in the treatment of rapidly progressive periodontitis.

Single dose and multidose analgesic study of ibuprofen and meclofenamate sodium after third molar surgery.[Pubmed:8284070]

Oral Surg Oral Med Oral Pathol. 1993 Dec;76(6):680-7.

The purpose of this study was to compare the analgesic efficacy and safety of Meclofenamate Sodium with ibuprofen after dental impaction surgery. This study was double-blind and used a unique methodology. Patients (N = 254) were first randomized into the single dose phase of the study that included placebo, meclofenamate 50 mg, meclofenamate 100 mg, ibuprofen 200 mg, and ibuprofen 400 mg, followed by a 7-day multidose phase in which patients in the placebo group were rerandomized into one of the active treatment cells. In the single dose phase, all active treatments were significantly more efficacious than placebo for every summary analgesic measure. A positive dose-response was seen for both active drugs with meclofenamate 100 mg and ibuprofen 400 mg exhibiting the greatest efficacy for pain relief, pain reduction, time to remedication, and overall evaluation. Side effects were reported by 26 patients. They were evenly distributed among treatment groups with headache and drowsiness being the most common. During the multidose phase, there were only small differences in efficacy measures among active treatment groups. However, meclofenamate produced a higher incidence of stomach cramps and diarrhea than did ibuprofen (8.8% and 7.2% versus 0.8% and 0.8%). This study indicates that higher doses of nonsteroidal anti-inflammatory drugs are most effective immediately after surgery and that lower doses of these drugs can be used after the first postoperative day. The side effect profile of nonsteroidal anti-inflammatory analgesics is best observed with the use of a multidose study design.

Different effects of the nonsteroidal anti-inflammatory drugs meclofenamate sodium and naproxen sodium on proteasome activity in cardiac cells.[Pubmed:27049794]

J Mol Cell Cardiol. 2016 May;94:131-144.

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) like Meclofenamate Sodium (MS), used to reduce pain, has been associated with an increased risk of cardiovascular disease (CVD). Naproxen (NAP), another NSAID, is not associated with increased risk of CVD. The molecular mechanism(s) by which NSAIDs induce CVD is unknown. We investigated the effects of MS and NAP on protein homeostasis and cardiotoxicity in rat cardiac H9c2 cells and murine neonatal cardiomyocytes. MS, but not NAP, significantly inhibited proteasome activity and reduced cardiac cell viability at pharmacological levels found in humans. Although proteasome subunit gene and protein expression were unaffected by NSAIDs, MS treated cell lysates showed higher 20S proteasome content, while purified proteasomes from MS treated cells had lower proteasome activity and higher levels of oxidized subunits than proteasomes from control cells. Addition of exogenous proteasome to MS treated cells improved cell viability. Both MS and NAP increased ROS production, but the rate of ROS production was greater in MS than in NAP treated cells. The ROS production is likely from mitochondria, as MS inhibited mitochondrial Complexes I and III, major sources of ROS, while NAP inhibited Complex I. MS also impaired mitochondrial membrane potential while NAP did not. Antioxidants were able to prevent the reduced cell viability caused by MS treatment. These results suggest that NSAIDs induce cardiotoxicity by a ROS dependent mechanism involving mitochondrial and proteasome dysfunction and may explain why some NSAIDs should not be given to patients for long periods.

Description

Meclofenamic acid sodium is a nonsteroidal anti-inflammatory drug (NSAID) approved for use in arthritis (osteo and rheumatoid), analgesia (mild to moderate pain), dysmenorrhea, and heavy menstrual blood loss (menorrhagia). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of fat mass and obesity-associated (FTO) enzyme inhibitor.

Keywords:

Meclofenamate Sodium,6385-02-0,Natural Products,COX, buy Meclofenamate Sodium , Meclofenamate Sodium supplier , purchase Meclofenamate Sodium , Meclofenamate Sodium cost , Meclofenamate Sodium manufacturer , order Meclofenamate Sodium , high purity Meclofenamate Sodium

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: